A Phase 2, Randomized, Open-Label, Controlled Trial to Evaluate the Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
Latest Information Update: 19 Apr 2026
At a glance
- Drugs HDM 1005 (Primary) ; Tirzepatide
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
Most Recent Events
- 19 Apr 2026 New trial record